Abstract 5775: Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong anti-tumor activity in wild-type and mutant ER+ breast cancer modelsMaysoun Shomali, Monsif Bouaboula, Frank Halley et al.|Cancer Research|2018Cited by 0